{"NCTID":"NCT05389293","clinicalTrial":{"derivedSection":{"conditionBrowseModule":{"ancestors":[{"id":"D008228","term":"Lymphoma, Non-Hodgkin"},{"id":"D009370","term":"Neoplasms by Histologic Type"},{"id":"D009369","term":"Neoplasms"},{"id":"D008232","term":"Lymphoproliferative Disorders"},{"id":"D008206","term":"Lymphatic Diseases"},{"id":"D006425","term":"Hemic and Lymphatic Diseases"},{"id":"D007160","term":"Immunoproliferative Disorders"},{"id":"D007154","term":"Immune System Diseases"}],"meshes":[{"id":"D008224","term":"Lymphoma, Follicular"},{"id":"D008223","term":"Lymphoma"}]},"interventionBrowseModule":{"meshes":[{"id":"C000629551","term":"zanubrutinib"}]},"miscInfoModule":{"versionHolder":"2026-03-10"}},"hasResults":false,"protocolSection":{"armsInterventionsModule":{"armGroups":[{"description":"Participants with newly diagnosed FL in need of systemic therapy","interventionNames":["Drug: Mosunetuzumab"],"label":"Single Agent Mosunetuzumab","type":"EXPERIMENTAL"},{"description":"Participants with newly diagnosed FL in need of systemic therapy","interventionNames":["Drug: Mosunetuzumab","Drug: Zanubrutinib"],"label":"Mosunetuzumab + Zanubrutinib","type":"EXPERIMENTAL"}],"interventions":[{"armGroupLabels":["Mosunetuzumab + Zanubrutinib","Single Agent Mosunetuzumab"],"description":"During Cycle 1, Mosunetuzumab will be administered SC in a step-up dosing schedule at the dose of 5 mg on Day 1, 45 mg on Day 8, and 45 mg on Day 15).\nBeginning with Cycle 2, Mosunetuzumab will be administered SC at the dose of 45 mg on Day 1.\nEach Cycle lasts 3 weeks.\nAfter the first 8 cycles (approximately 6 months) of therapy, subjects who achieved CR will discontinue therapy, those who attained a PR will receive up to 17 doses (approximately 12 months).\nSubjects who achieve stable disease (SD) or who experience progressive disease (PD) will be taken off study and subsequent management will be left at the discretion of the investigator.","name":"Mosunetuzumab","type":"DRUG"},{"armGroupLabels":["Mosunetuzumab + Zanubrutinib"],"description":"In Cohort 2, Zanubrutinib is concurrently administered continuously starting on Cycle 1, Day -7 and is given for 12 months in both patients with CR and those with PR.\nCohort 2 patients with evidence of circulating lymphoma cells at baseline will initiate Zanubrutinib dosing on Cycle 2 Day 1 and continue dosing for 12 months.","name":"Zanubrutinib","type":"DRUG"}]},"conditionsModule":{"conditions":["Follicular Lymphoma","Lymphoma"],"keywords":["Mosunetuzumab","Follicular Lymphoma","Lymphoma","Memorial Sloan Kettering Cancer Center","22-100"]},"contactsLocationsModule":{"centralContacts":[{"email":"FalchiL@mskcc.org","name":"Lorenzo Falchi, MD","phone":"646-608-3705","role":"CONTACT"},{"email":"SallesG@mskcc.org","name":"Gilles Salles, MD, PhD","phone":"646-608-4153","role":"CONTACT"}],"locations":[{"city":"Washington D.C.","contacts":[{"name":"Joseph Roswarski, MD","phone":"202-444-2223","role":"CONTACT"}],"country":"United States","facility":"Georgetown University (Data Collection Only)","geoPoint":{"lat":38.89511,"lon":-77.03637},"state":"District of Columbia","status":"RECRUITING","zip":"20007"},{"city":"Basking Ridge","contacts":[{"name":"Lorenzo Falchi, MD","phone":"646-608-3705","role":"CONTACT"}],"country":"United States","facility":"Memorial Sloan Kettering at Basking Ridge Limited Protocol Activities","geoPoint":{"lat":40.70621,"lon":-74.54932},"state":"New Jersey","status":"RECRUITING","zip":"07920"},{"city":"Hackensack","contacts":[{"name":"Lori Leslie, MD","phone":"551-996-3033","role":"CONTACT"}],"country":"United States","facility":"Hackensack Meridian Health (Data collection only)","geoPoint":{"lat":40.88593,"lon":-74.04347},"state":"New Jersey","status":"RECRUITING","zip":"07601"},{"city":"Middletown","contacts":[{"name":"Lorenzo Falchi, MD","phone":"646-608-3705","role":"CONTACT"}],"country":"United States","facility":"Memorial Sloan Kettering Monmouth (Limited protocol activities)","geoPoint":{"lat":40.39428,"lon":-74.11709},"state":"New Jersey","status":"RECRUITING","zip":"07748"},{"city":"Montvale","contacts":[{"name":"Lorenzo Falchi, MD","phone":"646-608-3705","role":"CONTACT"}],"country":"United States","facility":"Memorial Sloan Kettering Bergen (Limited Protocol Activities)","geoPoint":{"lat":41.04676,"lon":-74.02292},"state":"New Jersey","status":"RECRUITING","zip":"07645"},{"city":"Commack","contacts":[{"name":"Lorenzo Falchi, MD","phone":"646-608-3705","role":"CONTACT"}],"country":"United States","facility":"Memorial Sloan Kettering Suffolk- Commack (Limited protocol activities)","geoPoint":{"lat":40.84288,"lon":-73.29289},"state":"New York","status":"RECRUITING","zip":"11725"},{"city":"Harrison","contacts":[{"name":"Lorenzo Falchi, MD","phone":"646-608-3705","role":"CONTACT"}],"country":"United States","facility":"Memorial Sloan Kettering Westchester (Limited protocol activities)","geoPoint":{"lat":40.96899,"lon":-73.71263},"state":"New York","status":"RECRUITING","zip":"10604"},{"city":"New York","contacts":[{"email":"FalchiL@mskcc.org","name":"Lorenzo Falchi, MD","phone":"646-608-3705","role":"CONTACT"}],"country":"United States","facility":"Memorial Sloan Kettering Cancer Center","geoPoint":{"lat":40.71427,"lon":-74.00597},"state":"New York","status":"RECRUITING","zip":"10065"},{"city":"Rockville Centre","contacts":[{"name":"Lorenzo Falchi, MD","phone":"646-608-3705","role":"CONTACT"}],"country":"United States","facility":"Memorial Sloan Kettering Nassau (Limited protocol activities)","geoPoint":{"lat":40.65871,"lon":-73.64124},"state":"New York","status":"RECRUITING","zip":"11553"}],"overallOfficials":[{"affiliation":"Memorial Sloan Kettering Cancer Center","name":"Lorenzo Falchi, MD","role":"PRINCIPAL_INVESTIGATOR"}]},"descriptionModule":{"briefSummary":"The purpose of this study is to find out if mosunetuzumab is an effective treatment in people with follicular lymphoma that was recently diagnosed and have not yet received any treatments for their disease.","detailedDescription":"After completing enrollment of the initial 53 subjects, the researchers plan to expand the study by an additional 23 subjects."},"designModule":{"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"PARALLEL","maskingInfo":{"masking":"NONE"},"primaryPurpose":"TREATMENT"},"enrollmentInfo":{"count":152,"type":"ESTIMATED"},"phases":["PHASE2"],"studyType":"INTERVENTIONAL"},"eligibilityModule":{"eligibilityCriteria":"

Inclusion Criteria:

Signed Informed Consent Form(s)
Ability to comply with all the study-related procedures, in the investigator's judgement
Age 18 years or older
ECOG performance Status of 0, 1, or 2 [Appendix 2]
Untreated histologically documented FL of grade 1, 2, or 3A
Stage II bulky (noncontiguous), III, or IV bulky or high burden disease [Appendix 3]
Need of systemic therapy as evidenced by at least one of the following criteria [also see Appendix 4]:
- Bulky disease defined as:
- Nodal or extranodal mass > 7cm in maximum diameter
- ≥ 3 nodal or extranodal sites each with a diameter ≥ 3 cm
- Presence of any of the following constitutional symptoms:
- Fever (>38C) of unclear etiology
- Night sweats
- Weight loss >10% within the prior 6 months
- Symptomatic splenomegaly
- Mass-related symptoms
- End-organ damage (e.g., elevated creatinine or elevated liver enzymes) that is clearly related to lymphomatous infiltration in the opinion of the investigator
- Any one of the following cytopenias due to lymphoma:
- Hemoglobin < 10g/dL
- Platelets <100 x 10^9/L
- Absolute neutrophil count (ANC) < 1.5 x 10^9/L
- Pleural or peritoneal serous effusion (irrespective of cell content)
- Patients with absolute lymphocytosis ≥5,000 cells/µL in the peripheral blood may be allowed to participate after discussion with the study PI
Must be considered as a potential candidate for chemoimmunotherapy in the judgement of the treating physician
Must have at least one bi-dimensionally measurable lesion (>1.5 cm in its largest dimension for nodal lesions, or >1.0\ncm in its largest dimension for extranodal lesions by computerized tomography [CT] scan or MRI)
Agreement to provide tumor samples as follows:
- Agreement to undergo biopsy of a safely accessible tumor site per investigator determination prior to the first dose of mosunetuzumab.
- Agreement to undergo repeat biopsy of the same tumor site, if safely accessible, or a different safely accessible tumor site, per investigator determination, 14 to 21 days after the first dose of mosunetuzumab.
- Patients who are unable or unwilling to undergo either biopsy procedure may be allowed to participate in, or continue with, the study without any penalization after confirmation from the PI.\nInability to undergo a new pre-treatment or an on-treatment biopsy are not considered protocol violations.
Adequate hepatic function as follows: aspartate transaminase (AST) and alanine transaminase (ALT) levels ≤3 x upper limit of normal (ULN); total bilirubin level ≤1.5 x ULN (except with documented history of Gilbert syndrome)
Adequate bone marrow function as follows:
- Platelet count ≥75 x 10^9/L without transfusion within 14 days prior to first dose of mosunetuzumab;
- ANC ≥1 x 10^9/L
- Hemoglobin level ≥9 g/dL without transfusion within 14 days prior to the first dose of mosunetuzumab
- Patients who do not meet criteria for bone marrow function due to marrow involvement of lymphoma and/or other disease-related cytopenias (e.g., immune thrombocytopenia) may be enrolled into the study after discussion with, and confirmation by the PI.
Serum creatinine ≤ULN or estimated creatinine clearance ≥ 45 mL/min by Cockcroft-Gault method [see Appendix 5] or other institutional standard methods (e.g., based on nuclear medicine renal scan)
For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of ≤1% per year, and agreement to refrain from donating eggs, during the treatment period and for at least 3 months after the last dose of mosunetuzumab, and 3 months after the last dose of tocilizumab (if applicable), whichever is longer.
- A woman is considered to be of childbearing potential if she is post-menarcheal, has not reached a post-menopausal state (≥12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus).
- Examples of contraceptive methods with a failure rate of ≤1% per year include bilateral tubal ligation, male sterilization, established proper use of hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices.Hormonal contraception methods must be supplemented by a barrier method.
- The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient.\nPeriodic abstinence (e.g., calendar, ovulation, symptothermal, or post-ovulation methods) and withdrawal are not acceptable methods of contraception.
For men: agreement to remain abstinent (refrain from heterosexual intercourse), or use a condom, and agreement to refrain from donating sperm, as defined below:
- With female partners of childbearing potential or pregnant female partners, men must remain abstinent or use a condom during the treatment period and for at least 60 days after the last dose of mosunetuzumab and tocilizumab (if applicable) to avoid exposing the embryo.\nMen must refrain from donating sperm during this same period.
- The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient.\nPeriodic abstinence and withdrawal are not acceptable methods of contraception.

Exclusion Criteria:

Inability to comply with all the study-related procedures, in the investigator's judgement.
FL grade 3B or transformed FL
Patients not meeting criteria for systemic therapy as outlined in section 6.1 and Appendix 4
Patients unfit for chemoimmunotherapy for reasons including, but not limited to, advanced age and medical comorbidities
FL presenting with isolated extra-nodal localizations, such as duodenal FL, cutaneous FL or FL of the testis
Pediatric FL
Prior anti-lymphoma therapy
Prior solid organ transplantation
Prior allogeneic stem cell transplantation within 5 years of FL diagnosis.\nPreviously transplanted patients must be off all GVHD-related prophylaxis in order to be considered eligible.
Current or prior central nervous system (CNS) lymphoma
Current or past history of significant CNS disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease
- Patients with a history of stroke who have not experienced a stroke or transient ischemic attack in the past 2 years and have no residual neurologic deficits as judged by the investigator are allowed
- Patients with a history of epilepsy who have had no seizures in the past 2 years while not receiving any anti-epileptic medications are allowed
Significant cardiovascular disease such as New York Heart Association Class III or IV cardiac disease [see Appendix 6], myocardial infarction within the last 6 months, unstable arrhythmias, or unstable angina
Significant active pulmonary disease (e.g., bronchospasm or obstructive pulmonary disease)
Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 4 weeks prior to first mosunetuzumab administration
Known or suspected chronic active Epstein-Barr Virus infection
Serologic or PCR test results indicating acute or chronic HBV infection
° Patients whose HBV infection status cannot be determined by serologic test results (www.cdc.gov/hepatitis/hbv/pdfs/serologicchartv8.pdf) must be negative for HBV by PCR to be eligible for study participation.
Acute or chronic HCV infection
° Patients who are positive for HCV antibody must be negative for HCV by PCR to be eligible for study participation.
Serologic test results indicating HIV infection
Administration of a live, attenuated vaccine within 4 weeks before first dose of study treatment or anticipation that such a live attenuated vaccine will be required during the study
- Patients must not receive live, attenuated vaccines (e.g., FluMist®) while receiving study treatment or after the last dose until B-cell recovery to the normal ranges.\nKilled vaccines or toxoids should be given at least 4 weeks prior to the first dose of study treatment to allow development of sufficient immunity.
- Inactivated influenza vaccination during influenza season and the COVID-19 vaccination at any time are allowed.\nPlease see section 10.3.2 (permitted concomitant therapy) for additional guidance on SARS-CoV-2 vaccine administration and timing
- Investigators should review the vaccination status of potential study patients being considered for this study and follow the U.S. Centers for Disease Control and Prevention guidelines for adult vaccination with any other non-live vaccines intended to prevent infectious diseases prior to study.
Pregnant, lactating, or intending to become pregnant during the study or within 3 months after the last dose of mosunetuzumab and 3 months after the last dose of tocilizumab (if applicable)
° Women who are not postmenopausal (≥12 months of non-therapy-induced amenorrhea) or surgically sterile (removal of ovaries and/or uterus) must have a negative serum pregnancy test result within 14 days prior to initiation of study drug.\nIf a serum pregnancy test has not been performed within 14 days prior to receiving first study treatment, a negative urine pregnancy test result (performed within 7 days prior to study treatment) must be available.
Radiation therapy, unless utilized for the sole purpose of acutely controlling symptomatic disease during the screening period.\nIn this case, at least 2 weeks should lapse between the last radiation dose and the first mosunetuzumab administration and the patient must still have measurable disease outside the field of radiation prior to initiation of the study drug
Recent major surgery within 4 weeks prior to first mosunetuzumab administration, except protocol-mandated procedures (e.g., tumor biopsies and bone marrow biopsies)
History of autoimmune disease, including, but not limited to myocarditis, pneumonitis, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis
- Patients with a remote history of, or well-controlled autoimmune disease, may be eligible to enroll after discussion with and confirmation by the PI.
- Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study.
- Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone may be eligible for this study.
- Patients with a history of disease-related immune thrombocytopenic purpura or autoimmune hemolytic anemia may be eligible for this study.
- Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided all of following conditions are met:
- Rash must cover <10% of body surface area
- Disease is well controlled at baseline and requires only low-potency topical corticosteroids
- No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high potency or oral corticosteroids within the previous 12 months.
History of known HLH or suspected HLH in the opinion of the investigator
History of confirmed progressive multifocal leukoencephalopathy (PML)
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins)
History of other malignancy, except:
- Curatively treated basal cell carcinoma, squamous cell carcinoma of the skin, in situ cervical carcinoma, in situ prostatic neoplasia.
- A malignancy treated with curative intent and in remission for at least 2 years prior to the first mosunetuzumab administration
Receipt of systemic immunosuppressive medications (including but not limited to cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents) with the exception of corticosteroid treatment ≤10 mg/day prednisone or equivalent within 2 weeks prior to first dose of mosunetuzumab.\nThe following is permitted:
- The use of up to 12 mg/day dexamethasone for up to 3 days as antiemetic therapy
- The use of up to 1mg/kg of prednisone or equivalent for ≤7 days to control B symptoms
- The use of inhaled corticosteroids
- The use of mineralocorticoids for management of orthostatic hypotension
- The use of physiologic doses of corticosteroids for management of adrenal insufficiency
- The use of premedication corticosteroids prior to undergoing contrast-enhanced imaging studies, in patients who are allergic to contrast agents
History of illicit drug or alcohol abuse within 12 months prior to screening, in the investigator's judgment
Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's or PI's judgment, precludes the patient's safe participation in and completion of the study, or which could affect compliance with the protocol or interpretation of results

Cohort 2 only:

Requirement fors ongoing treatment with a strong CYP3A inhibitor or inducer (see section 15.2.3.2)
History of severe bleeding disorder such as hemophilia A, hemophilia B, von Willebrand disease, or history of spontaneous bleeding requiring blood transfusion or other medical intervention.
History of intracranial hemorrhage ≤ 180 days before the first dose of study treatment
Inability to swallow capsules clinically significant or gastrointestinal dysfunction such as demonstrated malabsorption syndrome, resection of the stomach or small bowel, bariatric surgery, symptomatic inflammatory bowel disease, or bowel obstruction.
Consumption of one or more of the following within 3 days prior to the first dose of zanubrutinib:
- Grapefruit or grapefruit products
- Seville oranges, including marmalade containing Seville oranges
- Star fruit (carambola)

","healthyVolunteers":false,"minimumAge":"18 Years","sex":"ALL","stdAges":["ADULT","OLDER_ADULT"]},"identificationModule":{"briefTitle":"A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma","nctId":"NCT05389293","officialTitle":"An Open-Label, Multicenter, Single-Arm, Sequential Phase-2 Study of Mosunetuzumab Alone or With Zanubrutinib for the Treatment of Patients With Newly Diagnosed Follicular Lymphoma in Need of Systemic Therapy","orgStudyIdInfo":{"id":"22-100"},"organization":{"class":"OTHER","fullName":"Memorial Sloan Kettering Cancer Center"}},"ipdSharingStatementModule":{"description":"Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials.\nThe protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov\nwhen required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required.\nRequests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication.\nDeidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals.\nRequests may be made to: crdatashare@mskcc.org.","ipdSharing":"YES"},"outcomesModule":{"primaryOutcomes":[{"description":"The primary objective of the study is to determine the rate of Complete Response/CR to single-agent SC mosunetuzumab according to the 2014 Lugano response criteria in participants with newly diagnosed Follicular Lymphoma in need of systemic therapy.","measure":"Rate of Complete Respons/CR","timeFrame":"Up to 1 year"}],"secondaryOutcomes":[{"description":"Assess the Overall Response Rate/ORR after treatment with single-agent SC mosunetuzumab mosunetuzumab","measure":"Overall Response Rate/ORR","timeFrame":"Up to 3 years"}]},"oversightModule":{"isFdaRegulatedDevice":false,"isFdaRegulatedDrug":true},"referencesModule":{"seeAlsoLinks":[{"label":"Memorial Sloan Kettering Cancer Center","url":"http://www.mskcc.org"}]},"sponsorCollaboratorsModule":{"leadSponsor":{"class":"OTHER","name":"Memorial Sloan Kettering Cancer Center"},"responsibleParty":{"type":"SPONSOR"}},"statusModule":{"completionDateStruct":{"date":"2026-12","type":"ESTIMATED"},"lastUpdatePostDateStruct":{"date":"2025-12-31","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-12-29","overallStatus":"RECRUITING","primaryCompletionDateStruct":{"date":"2026-12","type":"ESTIMATED"},"startDateStruct":{"date":"2022-05-27","type":"ACTUAL"},"statusVerifiedDate":"2025-12","studyFirstPostDateStruct":{"date":"2022-05-25","type":"ACTUAL"},"studyFirstSubmitDate":"2022-05-23","studyFirstSubmitQcDate":"2022-05-23"}}},"labeledClinicalTrialsCriteria":{"data":{"criteriaTree":{"id":"root","items":[{"id":"inclusion","items":[{"data":{"age":18,"operator":">=","type":"ageRule"},"hash":"[[\"age:18\",\"operator:>=\",\"type:ageRule\"]]","id":"rule_5986b4ce_60eb_48a4_a35d_0da9d40c5c2c","type":"rule"},{"data":{"max":2,"type":"ECOGRule"},"hash":"[[\"max:2\",\"type:ECOGRule\"]]","id":"rule_eacdf9ef_8a06_4659_9710_3f1cc0f0ee5f","type":"rule"}],"operator":"AND","type":"group"},{"id":"exclusion","items":[{"data":{"hasManualMappings":false,"mappings":[{"_type":"DocumentReference","path":"apps/curehub/conditionMappings/1148845007"}],"matchedTerm":"Follicular lymphoma grade 3B","negate":true,"operator":"INCLUDES_OR","relevantText":"FL grade 3B or transformed FL","resourceToUse":"mappings","searchTerms":["Follicular lymphoma grade 3B","FL grade 3B","Grade 3B follicular lymphoma"],"type":"conditionRule"},"hash":"[[\"hasManualMappings:false\",\"matchedTerm:Follicular lymphoma grade 3B\",\"operator:INCLUDES_OR\",\"resourceToUse:mappings\",\"searchTerms:Follicular lymphoma grade 3B,FL grade 3B,Grade 3B follicular lymphoma\",\"type:conditionRule\"],\"1148845007\"]","id":"rule_abfa358b_f38e_4d02_af6f_7dfafd254182","reasoning":"Patients with grade 3B follicular lymphoma are excluded.","type":"rule"},{"data":{"hasManualMappings":true,"mappings":[{"_type":"DocumentReference","path":"apps/curehub/manualMappings/transformed follicular lymphoma"},{"_type":"DocumentReference","path":"apps/curehub/manualMappings/transformed fl"}],"negate":true,"operator":"INCLUDES_OR","relevantText":"FL grade 3B or transformed FL","resourceToUse":"mappings","searchTerms":["Transformed follicular lymphoma","Transformed FL"],"type":"conditionRule"},"hash":"[[\"hasManualMappings:true\",\"matchedTerm:undefined\",\"operator:INCLUDES_OR\",\"resourceToUse:mappings\",\"searchTerms:Transformed follicular lymphoma,Transformed FL\",\"type:conditionRule\"],\"transformed fl\",\"transformed follicular lymphoma\"]","id":"rule_c3fd5f20_2e31_4bd2_a75b_379fa1e6fc13","reasoning":"Patients with transformed follicular lymphoma are excluded.","type":"rule"},{"data":{"hasManualMappings":true,"mappings":[{"_type":"DocumentReference","path":"apps/curehub/manualMappings/central nervous system lymphoma"},{"_type":"DocumentReference","path":"apps/curehub/manualMappings/cns lymphoma"}],"negate":true,"operator":"INCLUDES_OR","relevantText":"Current or prior central nervous system (CNS) lymphoma","resourceToUse":"mappings","searchTerms":["Central nervous system lymphoma","CNS lymphoma"],"type":"conditionRule"},"hash":"[[\"hasManualMappings:true\",\"matchedTerm:undefined\",\"operator:INCLUDES_OR\",\"resourceToUse:mappings\",\"searchTerms:Central nervous system lymphoma,CNS lymphoma\",\"type:conditionRule\"],\"central nervous system lymphoma\",\"cns lymphoma\"]","id":"rule_debac0e5_e2aa_4cf3_8820_6ca8e675ae9e","reasoning":"Any history of CNS lymphoma is excluded.","type":"rule"},{"data":{"hasManualMappings":false,"mappings":[{"_type":"DocumentReference","path":"apps/curehub/conditionMappings/230690007"}],"matchedTerm":"Stroke","negate":true,"operator":"INCLUDES_OR","relevantText":"Current or past history of significant CNS disease, such as stroke...","resourceToUse":"mappings","searchTerms":["Stroke","Cerebrovascular accident","CVA"],"type":"conditionRule"},"hash":"[[\"hasManualMappings:false\",\"matchedTerm:Stroke\",\"operator:INCLUDES_OR\",\"resourceToUse:mappings\",\"searchTerms:Stroke,Cerebrovascular accident,CVA\",\"type:conditionRule\"],\"230690007\"]","id":"rule_3c0fa390_a4eb_4f42_927f_b4e7caaeab82","reasoning":"History of stroke is an exclusion unless >2 years ago with no deficits.","type":"rule"},{"data":{"hasManualMappings":false,"mappings":[{"_type":"DocumentReference","path":"apps/curehub/conditionMappings/84757009"}],"matchedTerm":"Epilepsy","negate":true,"operator":"INCLUDES_OR","relevantText":"Current or past history of significant CNS disease, such as... epilepsy...","resourceToUse":"mappings","searchTerms":["Epilepsy","Seizure disorder"],"type":"conditionRule"},"hash":"[[\"hasManualMappings:false\",\"matchedTerm:Epilepsy\",\"operator:INCLUDES_OR\",\"resourceToUse:mappings\",\"searchTerms:Epilepsy,Seizure disorder\",\"type:conditionRule\"],\"84757009\"]","id":"rule_506b5898_8121_47ca_ad7a_d33aeaa7cf40","reasoning":"History of epilepsy is exclusion unless seizure‐free >2 years off meds.","type":"rule"},{"data":{"hasManualMappings":true,"mappings":[{"_type":"DocumentReference","path":"apps/curehub/manualMappings/central nervous system vasculitis"},{"_type":"DocumentReference","path":"apps/curehub/manualMappings/cns vasculitis"}],"negate":true,"operator":"INCLUDES_OR","relevantText":"Current or past history of significant CNS disease, such as... CNS vasculitis","resourceToUse":"mappings","searchTerms":["Central nervous system vasculitis","CNS vasculitis"],"type":"conditionRule"},"hash":"[[\"hasManualMappings:true\",\"matchedTerm:undefined\",\"operator:INCLUDES_OR\",\"resourceToUse:mappings\",\"searchTerms:Central nervous system vasculitis,CNS vasculitis\",\"type:conditionRule\"],\"central nervous system vasculitis\",\"cns vasculitis\"]","id":"rule_4c8ad14d_d3d3_4973_a8aa_082f91a8f0ef","reasoning":"History of CNS vasculitis is excluded.","type":"rule"},{"data":{"hasManualMappings":true,"mappings":[{"_type":"DocumentReference","path":"apps/curehub/manualMappings/neurodegenerative disease"},{"_type":"DocumentReference","path":"apps/curehub/manualMappings/neurodegenerative disorder"}],"negate":true,"operator":"INCLUDES_OR","relevantText":"Current or past history of significant CNS disease, such as... neurodegenerative disease","resourceToUse":"mappings","searchTerms":["Neurodegenerative disease","Neurodegenerative disorder"],"type":"conditionRule"},"hash":"[[\"hasManualMappings:true\",\"matchedTerm:undefined\",\"operator:INCLUDES_OR\",\"resourceToUse:mappings\",\"searchTerms:Neurodegenerative disease,Neurodegenerative disorder\",\"type:conditionRule\"],\"neurodegenerative disease\",\"neurodegenerative disorder\"]","id":"rule_2752fffd_ce60_4ffb_aa34_5da0fe94ef9b","reasoning":"Any neurodegenerative disease history excludes participation.","type":"rule"},{"data":{"hasManualMappings":false,"mappings":[{"_type":"DocumentReference","path":"apps/curehub/conditionMappings/84114007"}],"matchedTerm":"Heart failure","negate":true,"operator":"INCLUDES_OR","relevantText":"Significant cardiovascular disease such as New York Heart Association Class III or IV cardiac disease","resourceToUse":"mappings","searchTerms":["Heart failure","Congestive heart failure","NYHA Class III or IV cardiac disease"],"type":"conditionRule"},"hash":"[[\"hasManualMappings:false\",\"matchedTerm:Heart failure\",\"operator:INCLUDES_OR\",\"resourceToUse:mappings\",\"searchTerms:Heart failure,Congestive heart failure,NYHA Class III or IV cardiac disease\",\"type:conditionRule\"],\"84114007\"]","id":"rule_d687baa7_bb1f_460e_9be9_e867235ca37b","reasoning":"NYHA III/IV heart failure is exclusion.","type":"rule"},{"data":{"hasManualMappings":false,"mappings":[{"_type":"DocumentReference","path":"apps/curehub/conditionMappings/22298006"}],"matchedTerm":"Myocardial infarction","negate":true,"operator":"INCLUDES_OR","relevantText":"myocardial infarction within the last 6 months","resourceToUse":"mappings","searchTerms":["Myocardial infarction","MI","Heart attack"],"type":"conditionRule"},"hash":"[[\"hasManualMappings:false\",\"matchedTerm:Myocardial infarction\",\"operator:INCLUDES_OR\",\"resourceToUse:mappings\",\"searchTerms:Myocardial infarction,MI,Heart attack\",\"type:conditionRule\"],\"22298006\"]","id":"rule_9e31035d_3fb4_4874_98bc_b74850041ab6","reasoning":"Recent MI (<6 months) excludes patient.","type":"rule"},{"data":{"hasManualMappings":false,"mappings":[{"_type":"DocumentReference","path":"apps/curehub/conditionMappings/698247007"}],"matchedTerm":"Cardiac arrhythmia","negate":true,"operator":"INCLUDES_OR","relevantText":"unstable arrhythmias","resourceToUse":"mappings","searchTerms":["Cardiac arrhythmia","Arrhythmia","Unstable arrhythmias"],"type":"conditionRule"},"hash":"[[\"hasManualMappings:false\",\"matchedTerm:Cardiac arrhythmia\",\"operator:INCLUDES_OR\",\"resourceToUse:mappings\",\"searchTerms:Cardiac arrhythmia,Arrhythmia,Unstable arrhythmias\",\"type:conditionRule\"],\"698247007\"]","id":"rule_3f1f19b6_3979_4f49_a5ba_51e13793ca83","reasoning":"Unstable cardiac arrhythmias are excluded.","type":"rule"},{"data":{"hasManualMappings":false,"mappings":[{"_type":"DocumentReference","path":"apps/curehub/conditionMappings/194828000"}],"matchedTerm":"Angina pectoris","negate":true,"operator":"INCLUDES_OR","relevantText":"unstable angina","resourceToUse":"mappings","searchTerms":["Angina pectoris","Unstable angina"],"type":"conditionRule"},"hash":"[[\"hasManualMappings:false\",\"matchedTerm:Angina pectoris\",\"operator:INCLUDES_OR\",\"resourceToUse:mappings\",\"searchTerms:Angina pectoris,Unstable angina\",\"type:conditionRule\"],\"194828000\"]","id":"rule_3642c9e3_1a3c_4169_b38a_1bbe34062017","reasoning":"Unstable angina excludes participation.","type":"rule"},{"data":{"hasManualMappings":false,"mappings":[{"_type":"DocumentReference","path":"apps/curehub/conditionMappings/13645005"}],"matchedTerm":"Chronic obstructive pulmonary disease","negate":true,"operator":"INCLUDES_OR","relevantText":"Significant active pulmonary disease (e.g.,... obstructive pulmonary disease)","resourceToUse":"mappings","searchTerms":["Chronic obstructive pulmonary disease","COPD","Obstructive pulmonary disease"],"type":"conditionRule"},"hash":"[[\"hasManualMappings:false\",\"matchedTerm:Chronic obstructive pulmonary disease\",\"operator:INCLUDES_OR\",\"resourceToUse:mappings\",\"searchTerms:Chronic obstructive pulmonary disease,COPD,Obstructive pulmonary disease\",\"type:conditionRule\"],\"13645005\"]","id":"rule_b6037def_f8aa_4384_a691_ff8a7f470da3","reasoning":"Active obstructive pulmonary disease is exclusion.","type":"rule"},{"data":{"hasManualMappings":false,"mappings":[{"_type":"DocumentReference","path":"apps/curehub/conditionMappings/40733004"}],"matchedTerm":"Infection","negate":true,"operator":"INCLUDES_OR","relevantText":"Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection at study enrollment","resourceToUse":"mappings","searchTerms":["Active infection","Infection","Bacterial infection","Viral infection","Fungal infection","Mycobacterial infection","Parasitic infection"],"type":"conditionRule"},"hash":"[[\"hasManualMappings:false\",\"matchedTerm:Infection\",\"operator:INCLUDES_OR\",\"resourceToUse:mappings\",\"searchTerms:Active infection,Infection,Bacterial infection,Viral infection,Fungal infection,Mycobacterial infection,Parasitic infection\",\"type:conditionRule\"],\"40733004\"]","id":"rule_3a82627b_6a69_4aa4_a4dd_d05c9eedd70b","reasoning":"Any active infection at enrollment excludes patient.","type":"rule"},{"data":{"hasManualMappings":true,"mappings":[{"_type":"DocumentReference","path":"apps/curehub/manualMappings/chronic active epstein-barr virus infection"},{"_type":"DocumentReference","path":"apps/curehub/manualMappings/chronic active ebv infection"}],"negate":true,"operator":"INCLUDES_OR","relevantText":"Known or suspected chronic active Epstein-Barr Virus infection","resourceToUse":"mappings","searchTerms":["Chronic active Epstein-Barr virus infection","Chronic active EBV infection"],"type":"conditionRule"},"hash":"[[\"hasManualMappings:true\",\"matchedTerm:undefined\",\"operator:INCLUDES_OR\",\"resourceToUse:mappings\",\"searchTerms:Chronic active Epstein-Barr virus infection,Chronic active EBV infection\",\"type:conditionRule\"],\"chronic active ebv infection\",\"chronic active epstein-barr virus infection\"]","id":"rule_f080c66d_2527_4983_b7c4_912e14f147a7","reasoning":"Chronic active EBV infection is excluded.","type":"rule"},{"data":{"hasManualMappings":false,"mappings":[{"_type":"DocumentReference","path":"apps/curehub/conditionMappings/66071002"}],"matchedTerm":"Hepatitis B","negate":true,"operator":"INCLUDES_OR","relevantText":"Serologic or PCR test results indicating acute or chronic HBV infection","resourceToUse":"mappings","searchTerms":["Hepatitis B virus infection","HBV infection","Hepatitis B"],"type":"conditionRule"},"hash":"[[\"hasManualMappings:false\",\"matchedTerm:Hepatitis B\",\"operator:INCLUDES_OR\",\"resourceToUse:mappings\",\"searchTerms:Hepatitis B virus infection,HBV infection,Hepatitis B\",\"type:conditionRule\"],\"66071002\"]","id":"rule_11a64bb6_a190_4fa6_aea3_861116253943","reasoning":"Any acute or chronic HBV infection excludes participation.","type":"rule"},{"data":{"hasManualMappings":false,"mappings":[{"_type":"DocumentReference","path":"apps/curehub/conditionMappings/50711007"}],"matchedTerm":"Hepatitis C","negate":true,"operator":"INCLUDES_OR","relevantText":"Acute or chronic HCV infection","resourceToUse":"mappings","searchTerms":["Hepatitis C virus infection","HCV infection","Hepatitis C"],"type":"conditionRule"},"hash":"[[\"hasManualMappings:false\",\"matchedTerm:Hepatitis C\",\"operator:INCLUDES_OR\",\"resourceToUse:mappings\",\"searchTerms:Hepatitis C virus infection,HCV infection,Hepatitis C\",\"type:conditionRule\"],\"50711007\"]","id":"rule_4b07e838_907a_4742_b177_2beb7fe73c0f","reasoning":"Any acute or chronic HCV infection excludes patient.","type":"rule"},{"data":{"hasManualMappings":false,"mappings":[{"_type":"DocumentReference","path":"apps/curehub/conditionMappings/86406008"}],"matchedTerm":"HIV infection","negate":true,"operator":"INCLUDES_OR","relevantText":"Serologic test results indicating HIV infection","resourceToUse":"mappings","searchTerms":["HIV infection","Human immunodeficiency virus infection"],"type":"conditionRule"},"hash":"[[\"hasManualMappings:false\",\"matchedTerm:HIV infection\",\"operator:INCLUDES_OR\",\"resourceToUse:mappings\",\"searchTerms:HIV infection,Human immunodeficiency virus infection\",\"type:conditionRule\"],\"86406008\"]","id":"rule_39b92575_e0f0_4db5_a9b9_04c8c312ae45","reasoning":"HIV infection excludes patient.","type":"rule"},{"data":{"hasManualMappings":false,"mappings":[{"_type":"DocumentReference","path":"apps/curehub/conditionMappings/50920009"}],"matchedTerm":"Myocarditis","negate":true,"operator":"INCLUDES_OR","relevantText":"History of autoimmune disease, including, but not limited to, myocarditis","resourceToUse":"mappings","searchTerms":["Myocarditis","Inflammatory cardiomyopathy"],"type":"conditionRule"},"hash":"[[\"hasManualMappings:false\",\"matchedTerm:Myocarditis\",\"operator:INCLUDES_OR\",\"resourceToUse:mappings\",\"searchTerms:Myocarditis,Inflammatory cardiomyopathy\",\"type:conditionRule\"],\"50920009\"]","id":"rule_d8e95800_1d17_405b_826e_ce0d22372272","reasoning":"Autoimmune myocarditis history excludes participation.","type":"rule"},{"data":{"hasManualMappings":false,"mappings":[{"_type":"DocumentReference","path":"apps/curehub/conditionMappings/205237003"}],"matchedTerm":"Pneumonitis","negate":true,"operator":"INCLUDES_OR","relevantText":"History of autoimmune disease, including, but not limited to, ... pneumonitis","resourceToUse":"mappings","searchTerms":["Pneumonitis","Interstitial lung disease"],"type":"conditionRule"},"hash":"[[\"hasManualMappings:false\",\"matchedTerm:Pneumonitis\",\"operator:INCLUDES_OR\",\"resourceToUse:mappings\",\"searchTerms:Pneumonitis,Interstitial lung disease\",\"type:conditionRule\"],\"205237003\"]","id":"rule_0c471590_7e07_422e_9d3b_0ddd54be43a9","reasoning":"Autoimmune pneumonitis history is exclusion.","type":"rule"},{"data":{"hasManualMappings":false,"mappings":[{"_type":"DocumentReference","path":"apps/curehub/conditionMappings/91637004"}],"matchedTerm":"Myasthenia gravis","negate":true,"operator":"INCLUDES_OR","relevantText":"History of autoimmune disease, including, but not limited to, ... myasthenia gravis","resourceToUse":"mappings","searchTerms":["Myasthenia gravis"],"type":"conditionRule"},"hash":"[[\"hasManualMappings:false\",\"matchedTerm:Myasthenia gravis\",\"operator:INCLUDES_OR\",\"resourceToUse:mappings\",\"searchTerms:Myasthenia gravis\",\"type:conditionRule\"],\"91637004\"]","id":"rule_45002087_e001_401b_be31_53bfe616b88f","reasoning":"History of myasthenia gravis excludes patient.","type":"rule"},{"data":{"hasManualMappings":false,"mappings":[{"_type":"DocumentReference","path":"apps/curehub/conditionMappings/26889001"}],"matchedTerm":"Myositis","negate":true,"operator":"INCLUDES_OR","relevantText":"History of autoimmune disease, including, but not limited to, ... myositis","resourceToUse":"mappings","searchTerms":["Myositis"],"type":"conditionRule"},"hash":"[[\"hasManualMappings:false\",\"matchedTerm:Myositis\",\"operator:INCLUDES_OR\",\"resourceToUse:mappings\",\"searchTerms:Myositis\",\"type:conditionRule\"],\"26889001\"]","id":"rule_fc383370_b241_4279_863c_22b592385446","reasoning":"History of myositis excludes patient.","type":"rule"},{"data":{"hasManualMappings":false,"mappings":[{"_type":"DocumentReference","path":"apps/curehub/conditionMappings/408335007"}],"matchedTerm":"Autoimmune hepatitis","negate":true,"operator":"INCLUDES_OR","relevantText":"History of autoimmune disease, including, but not limited to, ... autoimmune hepatitis","resourceToUse":"mappings","searchTerms":["Autoimmune hepatitis"],"type":"conditionRule"},"hash":"[[\"hasManualMappings:false\",\"matchedTerm:Autoimmune hepatitis\",\"operator:INCLUDES_OR\",\"resourceToUse:mappings\",\"searchTerms:Autoimmune hepatitis\",\"type:conditionRule\"],\"408335007\"]","id":"rule_60350a1f_9e3c_4b86_a6cd_d93f13af0368","reasoning":"Autoimmune hepatitis history excludes participation.","type":"rule"},{"data":{"hasManualMappings":false,"mappings":[{"_type":"DocumentReference","path":"apps/curehub/conditionMappings/55464009"}],"matchedTerm":"Systemic lupus erythematosus","negate":true,"operator":"INCLUDES_OR","relevantText":"History of autoimmune disease, including, but not limited to, ... systemic lupus erythematosus","resourceToUse":"mappings","searchTerms":["Systemic lupus erythematosus","SLE"],"type":"conditionRule"},"hash":"[[\"hasManualMappings:false\",\"matchedTerm:Systemic lupus erythematosus\",\"operator:INCLUDES_OR\",\"resourceToUse:mappings\",\"searchTerms:Systemic lupus erythematosus,SLE\",\"type:conditionRule\"],\"55464009\"]","id":"rule_cd663181_41b4_4dbc_b433_758dcc8ccdd7","reasoning":"History of SLE excludes patient.","type":"rule"},{"data":{"hasManualMappings":false,"mappings":[{"_type":"DocumentReference","path":"apps/curehub/conditionMappings/69896004"}],"matchedTerm":"Rheumatoid arthritis","negate":true,"operator":"INCLUDES_OR","relevantText":"History of autoimmune disease, including, but not limited to, ... rheumatoid arthritis","resourceToUse":"mappings","searchTerms":["Rheumatoid arthritis"],"type":"conditionRule"},"hash":"[[\"hasManualMappings:false\",\"matchedTerm:Rheumatoid arthritis\",\"operator:INCLUDES_OR\",\"resourceToUse:mappings\",\"searchTerms:Rheumatoid arthritis\",\"type:conditionRule\"],\"69896004\"]","id":"rule_104a0555_4885_4ac2_8fef_588c480613b4","reasoning":"History of rheumatoid arthritis excludes participation.","type":"rule"},{"data":{"hasManualMappings":false,"mappings":[{"_type":"DocumentReference","path":"apps/curehub/conditionMappings/24526004"}],"matchedTerm":"Inflammatory bowel disease","negate":true,"operator":"INCLUDES_OR","relevantText":"History of autoimmune disease, including, but not limited to, ... inflammatory bowel disease","resourceToUse":"mappings","searchTerms":["Inflammatory bowel disease","IBD"],"type":"conditionRule"},"hash":"[[\"hasManualMappings:false\",\"matchedTerm:Inflammatory bowel disease\",\"operator:INCLUDES_OR\",\"resourceToUse:mappings\",\"searchTerms:Inflammatory bowel disease,IBD\",\"type:conditionRule\"],\"24526004\"]","id":"rule_6da45967_7569_4165_9c86_0605d1280afb","reasoning":"History of IBD excludes patient.","type":"rule"},{"data":{"hasManualMappings":false,"mappings":[{"_type":"DocumentReference","path":"apps/curehub/conditionMappings/26843008"}],"matchedTerm":"Antiphospholipid syndrome","negate":true,"operator":"INCLUDES_OR","relevantText":"History of autoimmune disease, including, but not limited to, vascular thrombosis associated with antiphospholipid syndrome","resourceToUse":"mappings","searchTerms":["Antiphospholipid syndrome"],"type":"conditionRule"},"hash":"[[\"hasManualMappings:false\",\"matchedTerm:Antiphospholipid syndrome\",\"operator:INCLUDES_OR\",\"resourceToUse:mappings\",\"searchTerms:Antiphospholipid syndrome\",\"type:conditionRule\"],\"26843008\"]","id":"rule_ad0e3212_19db_47fd_9adc_094759b2354f","reasoning":"Antiphospholipid syndrome history is exclusion.","type":"rule"},{"data":{"hasManualMappings":false,"mappings":[{"_type":"DocumentReference","path":"apps/curehub/conditionMappings/195353004"}],"matchedTerm":"Granulomatosis with polyangiitis","negate":true,"operator":"INCLUDES_OR","relevantText":"History of autoimmune disease, including, but not limited to, ... Wegener's granulomatosis","resourceToUse":"mappings","searchTerms":["Granulomatosis with polyangiitis","Wegener's granulomatosis"],"type":"conditionRule"},"hash":"[[\"hasManualMappings:false\",\"matchedTerm:Granulomatosis with polyangiitis\",\"operator:INCLUDES_OR\",\"resourceToUse:mappings\",\"searchTerms:Granulomatosis with polyangiitis,Wegener's granulomatosis\",\"type:conditionRule\"],\"195353004\"]","id":"rule_021dcc4e_fe72_4658_89a3_7075b292a321","reasoning":"History of granulomatosis with polyangiitis excludes patient.","type":"rule"},{"data":{"hasManualMappings":false,"mappings":[{"_type":"DocumentReference","path":"apps/curehub/conditionMappings/83901003"}],"matchedTerm":"Sjögren's syndrome","negate":true,"operator":"INCLUDES_OR","relevantText":"History of autoimmune disease, including, but not limited to, Sjögren's syndrome","resourceToUse":"mappings","searchTerms":["Sjögren's syndrome"],"type":"conditionRule"},"hash":"[[\"hasManualMappings:false\",\"matchedTerm:Sjögren's syndrome\",\"operator:INCLUDES_OR\",\"resourceToUse:mappings\",\"searchTerms:Sjögren's syndrome\",\"type:conditionRule\"],\"83901003\"]","id":"rule_89ef373c_3ca5_4cef_aef7_974f9e4ce1a3","reasoning":"History of Sjögren's syndrome excludes participation.","type":"rule"},{"data":{"hasManualMappings":true,"mappings":[{"_type":"DocumentReference","path":"apps/curehub/manualMappings/guillain–barré syndrome"}],"negate":true,"operator":"INCLUDES_OR","relevantText":"History of autoimmune disease, including, but not limited to, Guillain-Barré syndrome","resourceToUse":"mappings","searchTerms":["Guillain–Barré syndrome"],"type":"conditionRule"},"hash":"[[\"hasManualMappings:true\",\"matchedTerm:undefined\",\"operator:INCLUDES_OR\",\"resourceToUse:mappings\",\"searchTerms:Guillain–Barré syndrome\",\"type:conditionRule\"],\"guillain–barré syndrome\"]","id":"rule_7eb49554_a46f_4969_8bf1_868d14770fda","reasoning":"History of Guillain–Barré syndrome excludes patient.","type":"rule"},{"data":{"hasManualMappings":false,"mappings":[{"_type":"DocumentReference","path":"apps/curehub/conditionMappings/192929006"}],"matchedTerm":"Multiple sclerosis","negate":true,"operator":"INCLUDES_OR","relevantText":"History of autoimmune disease, including, but not limited to, multiple sclerosis","resourceToUse":"mappings","searchTerms":["Multiple sclerosis","MS"],"type":"conditionRule"},"hash":"[[\"hasManualMappings:false\",\"matchedTerm:Multiple sclerosis\",\"operator:INCLUDES_OR\",\"resourceToUse:mappings\",\"searchTerms:Multiple sclerosis,MS\",\"type:conditionRule\"],\"192929006\"]","id":"rule_8c854a72_c5b7_4295_80ec_8afd33d90f35","reasoning":"History of multiple sclerosis is exclusion.","type":"rule"},{"data":{"hasManualMappings":false,"mappings":[{"_type":"DocumentReference","path":"apps/curehub/conditionMappings/31996006"}],"matchedTerm":"Vasculitis","negate":true,"operator":"INCLUDES_OR","relevantText":"History of autoimmune disease, including, but not limited to, vasculitis","resourceToUse":"mappings","searchTerms":["Vasculitis"],"type":"conditionRule"},"hash":"[[\"hasManualMappings:false\",\"matchedTerm:Vasculitis\",\"operator:INCLUDES_OR\",\"resourceToUse:mappings\",\"searchTerms:Vasculitis\",\"type:conditionRule\"],\"31996006\"]","id":"rule_878fe2d9_78a3_4761_ab83_572874b2d839","reasoning":"History of vasculitis excludes participation.","type":"rule"},{"data":{"hasManualMappings":false,"mappings":[{"_type":"DocumentReference","path":"apps/curehub/conditionMappings/36171008"}],"matchedTerm":"Glomerulonephritis","negate":true,"operator":"INCLUDES_OR","relevantText":"History of autoimmune disease, including, but not limited to, glomerulonephritis","resourceToUse":"mappings","searchTerms":["Glomerulonephritis"],"type":"conditionRule"},"hash":"[[\"hasManualMappings:false\",\"matchedTerm:Glomerulonephritis\",\"operator:INCLUDES_OR\",\"resourceToUse:mappings\",\"searchTerms:Glomerulonephritis\",\"type:conditionRule\"],\"36171008\"]","id":"rule_ab8178bc_ca77_4660_a52f_adcbe2e2e20e","reasoning":"History of glomerulonephritis excludes patient.","type":"rule"},{"data":{"hasManualMappings":false,"mappings":[{"_type":"DocumentReference","path":"apps/curehub/conditionMappings/234437005"}],"matchedTerm":"Hemophagocytic lymphohistiocytosis","negate":true,"operator":"INCLUDES_OR","relevantText":"History of known HLH or suspected HLH in the opinion of the investigator","resourceToUse":"mappings","searchTerms":["Hemophagocytic lymphohistiocytosis","HLH"],"type":"conditionRule"},"hash":"[[\"hasManualMappings:false\",\"matchedTerm:Hemophagocytic lymphohistiocytosis\",\"operator:INCLUDES_OR\",\"resourceToUse:mappings\",\"searchTerms:Hemophagocytic lymphohistiocytosis,HLH\",\"type:conditionRule\"],\"234437005\"]","id":"rule_eda81fc3_1506_409c_bb8b_a2a80e5a4b05","reasoning":"History or suspicion of HLH excludes participation.","type":"rule"},{"data":{"hasManualMappings":false,"mappings":[{"_type":"DocumentReference","path":"apps/curehub/conditionMappings/22255007"}],"matchedTerm":"Progressive multifocal leukoencephalopathy","negate":true,"operator":"INCLUDES_OR","relevantText":"History of confirmed progressive multifocal leukoencephalopathy (PML)","resourceToUse":"mappings","searchTerms":["Progressive multifocal leukoencephalopathy","PML"],"type":"conditionRule"},"hash":"[[\"hasManualMappings:false\",\"matchedTerm:Progressive multifocal leukoencephalopathy\",\"operator:INCLUDES_OR\",\"resourceToUse:mappings\",\"searchTerms:Progressive multifocal leukoencephalopathy,PML\",\"type:conditionRule\"],\"22255007\"]","id":"rule_0140fd3b_e2a4_4e4f_a6b0_1aaff0d30de6","reasoning":"History of PML excludes patient.","type":"rule"},{"data":{"hasManualMappings":false,"mappings":[{"_type":"DocumentReference","path":"apps/curehub/conditionMappings/1306691007"}],"matchedTerm":"Substance use disorder","negate":true,"operator":"INCLUDES_OR","relevantText":"History of illicit drug or alcohol abuse within 12 months prior to screening","resourceToUse":"mappings","searchTerms":["Substance use disorder","Alcohol abuse","Illicit drug abuse"],"type":"conditionRule"},"hash":"[[\"hasManualMappings:false\",\"matchedTerm:Substance use disorder\",\"operator:INCLUDES_OR\",\"resourceToUse:mappings\",\"searchTerms:Substance use disorder,Alcohol abuse,Illicit drug abuse\",\"type:conditionRule\"],\"1306691007\"]","id":"rule_0cd0a066_2ea0_452f_a988_bdbe644ae06c","reasoning":"Recent substance abuse history excludes participation.","type":"rule"},{"data":{"hasManualMappings":false,"mappings":[{"_type":"DocumentReference","path":"apps/curehub/conditionMappings/28293008"}],"matchedTerm":"Hemophilia A","negate":true,"operator":"INCLUDES_OR","relevantText":"History of severe bleeding disorder such as hemophilia A","resourceToUse":"mappings","searchTerms":["Hemophilia A"],"type":"conditionRule"},"hash":"[[\"hasManualMappings:false\",\"matchedTerm:Hemophilia A\",\"operator:INCLUDES_OR\",\"resourceToUse:mappings\",\"searchTerms:Hemophilia A\",\"type:conditionRule\"],\"28293008\"]","id":"rule_4945f9c0_e5d9_429f_be6c_78cef4d1cd2e","reasoning":"Hemophilia A is a severe bleeding disorder exclusion.","type":"rule"},{"data":{"hasManualMappings":false,"mappings":[{"_type":"DocumentReference","path":"apps/curehub/conditionMappings/41788008"}],"matchedTerm":"Hemophilia B","negate":true,"operator":"INCLUDES_OR","relevantText":"History of severe bleeding disorder such as ... hemophilia B","resourceToUse":"mappings","searchTerms":["Hemophilia B"],"type":"conditionRule"},"hash":"[[\"hasManualMappings:false\",\"matchedTerm:Hemophilia B\",\"operator:INCLUDES_OR\",\"resourceToUse:mappings\",\"searchTerms:Hemophilia B\",\"type:conditionRule\"],\"41788008\"]","id":"rule_906e8c10_8cb9_4dbf_820f_0616013300ce","reasoning":"Hemophilia B is an exclusion criterion.","type":"rule"},{"data":{"hasManualMappings":false,"mappings":[{"_type":"DocumentReference","path":"apps/curehub/conditionMappings/128105004"}],"matchedTerm":"von Willebrand disease","negate":true,"operator":"INCLUDES_OR","relevantText":"History of severe bleeding disorder such as ... von Willebrand disease","resourceToUse":"mappings","searchTerms":["von Willebrand disease"],"type":"conditionRule"},"hash":"[[\"hasManualMappings:false\",\"matchedTerm:von Willebrand disease\",\"operator:INCLUDES_OR\",\"resourceToUse:mappings\",\"searchTerms:von Willebrand disease\",\"type:conditionRule\"],\"128105004\"]","id":"rule_9d9c2c70_12dc_475e_a65e_bf1296a16eb0","reasoning":"Von Willebrand disease excludes participation.","type":"rule"},{"data":{"hasManualMappings":false,"mappings":[{"_type":"DocumentReference","path":"apps/curehub/conditionMappings/32230006"}],"matchedTerm":"Malabsorption syndrome","negate":true,"operator":"INCLUDES_OR","relevantText":"gastrointestinal dysfunction such as malabsorption syndrome","resourceToUse":"mappings","searchTerms":["Malabsorption syndrome"],"type":"conditionRule"},"hash":"[[\"hasManualMappings:false\",\"matchedTerm:Malabsorption syndrome\",\"operator:INCLUDES_OR\",\"resourceToUse:mappings\",\"searchTerms:Malabsorption syndrome\",\"type:conditionRule\"],\"32230006\"]","id":"rule_e880eb18_be2a_4811_9b01_da96e92a21cd","reasoning":"Malabsorption syndrome is exclusion for inability to absorb capsules.","type":"rule"},{"data":{"hasManualMappings":false,"mappings":[{"_type":"DocumentReference","path":"apps/curehub/conditionMappings/81060008"}],"matchedTerm":"Bowel obstruction","negate":true,"operator":"INCLUDES_OR","relevantText":"gastrointestinal dysfunction such as... bowel obstruction","resourceToUse":"mappings","searchTerms":["Bowel obstruction","Intestinal obstruction"],"type":"conditionRule"},"hash":"[[\"hasManualMappings:false\",\"matchedTerm:Bowel obstruction\",\"operator:INCLUDES_OR\",\"resourceToUse:mappings\",\"searchTerms:Bowel obstruction,Intestinal obstruction\",\"type:conditionRule\"],\"81060008\"]","id":"rule_3ae1c3a9_7488_49e9_b11b_10d3afe20aab","reasoning":"Bowel obstruction excludes patient.","type":"rule"},{"data":{"mappings":[{"_type":"DocumentReference","path":"apps/curehub/medicationMappings/1256"}],"negate":true,"operator":"INCLUDES_OR","relevantText":"Receipt of systemic immunosuppressive medications (including but not limited to cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents) with the exception of corticosteroid treatment ≤10 mg/day prednisone or equivalent within 2 weeks prior to first dose of mosunetuzumab.","resourceToUse":"mappings","type":"medicationRule"},"hash":"[[\"operator:INCLUDES_OR\",\"resourceToUse:mappings\",\"type:medicationRule\"],\"1256\"]","id":"rule_4d70f9c6_f15a_4f56_9a30_0242ff4bdf90","reasoning":"Azathioprine is explicitly listed as a systemic immunosuppressive that excludes the patient.","type":"rule"},{"data":{"mappings":[{"_type":"DocumentReference","path":"apps/curehub/medicationMappings/3002"}],"negate":true,"operator":"INCLUDES_OR","relevantText":"Receipt of systemic immunosuppressive medications (including but not limited to cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents) with the exception of corticosteroid treatment ≤10 mg/day prednisone or equivalent within 2 weeks prior to first dose of mosunetuzumab.","resourceToUse":"mappings","type":"medicationRule"},"hash":"[[\"operator:INCLUDES_OR\",\"resourceToUse:mappings\",\"type:medicationRule\"],\"3002\"]","id":"rule_377a0dd6_4445_4494_914b_ffaeb5a5d41a","reasoning":"Cyclophosphamide is explicitly listed as a systemic immunosuppressive that excludes the patient.","type":"rule"}],"operator":"OR","type":"group"}],"type":"group"},"disease":{"_type":"DocumentReference","path":"diseases/hodgkin-lymphoma"},"hasManualMappings":true,"nctId":"NCT05389293","sourceBatch":{"_type":"DocumentReference","path":"apps/clinicalTrials/clinicalTrialsBatches/batch_68a8388880548190a0df31acb8c14a35"},"status":"RECRUITING","updatedAt":{"_type":"Date","value":"Mon Sep 29 2025 09:02:06 GMT+0000 (Coordinated Universal Time)"},"version":"v3.1"},"included":{},"ref":{"_type":"DocumentReference","path":"apps/clinicalTrials/clinicalTrialsTrees/NCT05389293-hodgkin-lymphoma"},"snapshot":{"exists":true,"id":"NCT05389293-hodgkin-lymphoma","ref":{"_type":"DocumentReference","path":"apps/clinicalTrials/clinicalTrialsTrees/NCT05389293-hodgkin-lymphoma"}}}}

Introduction

BPDCN Overview

BPDCN Signs and Symptoms

Genetic Changes and BPDCN

Diagnosing BPDCN

BPDCN Treatment Overview

Living with BPDCN

Expert Perspectives on BPDCN